Careers Contact Us Home About us Our Pipeline Our Science Partnering News & Events Crescendo > About us > Leadership Team Leadership Team Leadership Team Crescendo Biologics’ leadership team has extensive industry experience from companies such as Roche, GSK, MedImmune, Cambridge Antibody Technology and AstraZeneca. The team has a strong entrepreneurial approach with a track-record of success in bringing multiple immunotherapies and other antibody-related therapeutics to the clinic. Theodora Harold CEO Dr Philip Bland-Ward CDO Julia Tilson COO Dr Kenji Hashimoto CMO Dr Michael Booth CFO Dr Richard Williams SVP CMC and Development Dr Andrew Pierce VP of Translational Biology Dr Colette Johnston Senior Director of Research Dr Laurie Galson-Holt Associate Director of BD and IP Humabody® and Multibody® are registered trademarks of Crescendo Biologics Ltd. Meditrina Building 260, Babraham Research Campus, Cambridge, CB22 3AT Cambridge Web Design We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok

Careers Contact Us Home About us Our Pipeline Our Science Partnering News & Events Crescendo > Our Pipeline Our Pipeline Our Pipeline – Overview Crescendo is developing novel Humabody® therapeutics capable of delivering safer, more durable anti-cancer responses in patients with hard to treat cancers. Its pipeline has broad applicability across a range of key oncology indications with a focus on novel, targeted T cell activation. Crescendo’s lead programme is CB307, a novel bispecific PSMA-targeted T cell engager for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment through the CD137 (4-1BB) co-stimulatory mechanism. Humabody® and Multibody® are registered trademarks of Crescendo Biologics Ltd. Meditrina Building 260, Babraham Research Campus, Cambridge, CB22 3AT Cambridge Web Design

Careers Contact Us Home About us Our Pipeline Our Science Partnering News & Events Crescendo > Partnering Overview > Humabody® Technology Applications Humabody® Technology Applications Humabody® Technology Applications The Humabody platform is exceptionally versatile and has advantages in a broad range of both technology applications and disease areas. Crescendo is actively seeking to expand its partnerships in both of these areas. MultiBody® Therapeutics mAb Fusions CAR-T Humabody Drug Conjugates Radionuclides Oncolytic Viruses Using its extensive in-house expertise, Crescendo is able to combine multiple Humabody V into novel multi-specific formats that are expressed as a single construct. Crescendo can identify optimal configurations to access novel biology in ways that would be extremely challenging or impossible using whole antibodies. We have used this technology to generate our IO pipeline of T cell enhancing mulitspecifics. To explore ways in which we could help you achieve your drug development goals, please contact us. Humabody® and Multibody® are registered trademarks of Crescendo Biologics Ltd. Meditrina Building 260, Babraham Research Campus, Cambridge, CB22 3AT Cambridge Web Design